Expert opinion on sonidegib efficacy, safety and tolerability

References

• Cameron MC, Lee E, Hibler BP. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303–317.
   PubMed Web of Science ®Google Scholar
• Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–287.
   PubMed Web of Science ®Google Scholar
• Guy GP, Machlin SR, Ekwueme DU, et al. Prevalence and costs of skin cancer treatment in the US, 2002–2006 and 2007–2011. Am J Prev Med. 2015;48(2):183–187
   PubMed Web of Science ®Google Scholar
• Youssef KK, Van Keymeulen A, Lapouge G, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010;12(3):299–305.
   PubMed Web of Science ®Google Scholar
• Lang BM, Balermpas P, Bauer A, et al. S2k guidelines for cutaneous basal cell carcinoma—part 1: epidemiology, genetics and diagnosis: S2k guidelines for basal cell carcinoma— part 1. JDDG J Dtsch Dermatol Ges. 2019;17:94–103.
   Web of Science ®Google Scholar
• Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63(1–3):8–18.
   PubMed Web of Science ®Google Scholar
• Niebel D, Sirokay J, Hoffmann F, et al. Clinical management of locally advanced basal-cell carcinomas and future therapeutic directions. Dermatol Ther (Heidelb). 2020;10(4):835–846.
   PubMed Web of Science ®Google Scholar
• Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines. Eur J Cancer. 2019;118:10–34.
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Safety and efficacy in treatment of advanced basal cell carcinoma. Dermatol Ther (Heidelb). 2020 Jun;10(3):401–412.
   PubMed Web of Science ®Google Scholar
• Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111(8):1476–1481.
   PubMed Web of Science ®Google Scholar
• Telfer NR, Colver GB, Morton CA. British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159(1):35–48.
   PubMed Web of Science ®Google Scholar
• Villani A, Cinelli E, Fabbrocini G, et al. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opin Drug Saf. 2020 Dec;1912:1585–1594. Epub 2020 Oct 22
   PubMed Web of Science ®Google Scholar
• Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2016;8(5):375–382.
   PubMed Web of Science ®Google Scholar
• Genentech (2015) Erivedge_ (vismodegib) capsules, for oral use: US pre-scribing infomation. https://www.erivedge.com/. Accessed 2016 Jan 13
   Google Scholar
• European Medicines Agency (2015) Erivedge 150 mg hard capsules: summary of product characteristics. https://www.ema.europa.eu/. Accessed 2016 Jan 13
   Google Scholar
• Novartis (2015) Odomzo_ (sonidegib) capsules, for oral use: US prescribing infomation. www.odomzo.com/. Accessed 2015 Jan 13
   Google Scholar
• European Medicines Agency (2015) Odomzo_ 200 mg hard capsules: summary of product characteristics. https://www.ema.europa.eu/. Accessed 2016 Jan 13
   Google Scholar
• Villani A, Megna M, Fabbrocini G, et al. Long-term efficacy of vismodegib after its withdrawal and patients’ health-related quality of life using the Dermatology Life Quality Index (DLQI). Dermatol Ther (Heidelb). 2019 Dec 9;94:719–724.
   PubMed Web of Science ®Google Scholar
• Nu¨sslein-volhard C, Wieschaus E. Mutation’s affecting segment number and polarity in drosophila. Nature. 1980;287(5785):795–801.
   PubMed Web of Science ®Google Scholar
• Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–754.
   PubMed Web of Science ®Google Scholar
• Tang JY, So PL, Epstein EH. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol. 2007;224(3):257–264.
   PubMed Web of Science ®Google Scholar
• Burness CB. Sonidegib: first global approval. Drugs. 2015;75(13):1559–1566.
   PubMed Web of Science ®Google Scholar
• Zollinger M, Lozac’h F, Hurh E, et al. Absorption, distribution, metabolism, and excretion (ADME) of (1)(4)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol. 2014;74(1):63–75.
   PubMed Web of Science ®Google Scholar
• Rodon J, Ha T, Al T, et al. multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900–1909.
   PubMed Web of Science ®Google Scholar
• Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–728.
   PubMed Web of Science ®Google Scholar
• Pan S, Wu X, Jiang J, et al. Discovery of NVPLDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett. 2010;1(3):130–134.
   PubMed Web of Science ®Google Scholar
• Goel V, Hurh E, Stein A, et al. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(4):745–755.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim AH, Yoon S, et al. The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects. Drug Metab Pharmacokinet. 2021 Feb;36:100368. DOI:https://doi.org/10.1016/j.dmpk.2020.11.003.
   Google Scholar
• Chen L, Silapunt S, Migden MR. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016;12(18):2095–2105.
   PubMed Web of Science ®Google Scholar
• Lear J, Guminski A, Gutzmer R. A phase 2, randomized, double-blind study of sonidegib (LDE225) in patients with advanced basal cell carcinoma: the BOLT 18-month analysis [abstract]. In 24th EADV congress. 2015.
   Google Scholar
• Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–381.
   PubMed Web of Science ®Google Scholar
• Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2019; DOI:https://doi.org/10.1111/bjd.18552.
   Google Scholar
• Dummer R, Lear JT, Guminski A, et al. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: results from the final analysis of the randomized phase 2 basal cell carcinoma outcomes with LDE225 Treatment (BOLT) trial at 42 months. J Am Acad Dermatol. 2020 Dec 23;84(4):SS0190–6.
   Web of Science ®Google Scholar
• Ramelyte E, Restivo G, Imhof L, et al. How to break resistance to hedgehog inhibitors in advanced basal cell carcinoma? Br J Dermatol. 2020 Aug 31;184(2):359–361.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1944–1956.
   PubMed Web of Science ®Google Scholar
• Villani A, Fabbrocini G, Costa C, et al. Complete remission of an advanced basal cell carcinoma after only 3-month treatment with sonidegib: report of a case and drug management during COVID-19 pandemic. Dermatol Ther. 2020 Nov;33(6):e14200.
   PubMed Web of Science ®Google Scholar
• Villani A, Costa C, Fabbrocini G, et al. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: a retrospective case series. J Am Acad Dermatol. 2020 Dec 7;S0190-9622(20)33150–9. https://doi.org/10.1016/j.jaad.2020.12.006.
   Google Scholar
• Conforti C, Giuffrida R, Di Meo N, et al. Management of locally advanced basal cell carcinoma treated with sonidegib: the experience of an Italian reference hospital. Dermatol Ther. 2020 Nov;33(6):e14511. .
   PubMed Web of Science ®Google Scholar
• Scalvenzi M, Villani A, Mazzella C, et al. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018 Nov-Dec;84(6):758–760. .
   PubMed Web of Science ®Google Scholar